Drug therapy and nutritional management of metabolic syndrome associated with hyperadrenocorticism in a dog – case report

2017 ◽  
Vol XXII (131) ◽  
pp. 38-46
Author(s):  
Viviani De Marco ◽  
Elidia Zotelli dos Santos
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Arterial Hypertension ◽  
Systemic Arterial Hypertension ◽  
The Metabolic Syndrome ◽  
Generic Term ◽  
High Concentrations ◽  
Stable Control ◽  
Biochemical Abnormalities

Hyperadrenocorticism (HAC) is a generic term that refers to clinical and biochemical abnormalities resulting from persistently high concentrations of glucocorticoids in the bloodstream, which may occur spontaneously or iatrogenically. Chronic hypercortisolism may promote abdominal obesity, dyslipidemia, systemic arterial hypertension and insulin resistance, abnormalities associated with the metabolic syndrome (MS). The present study aims to report the presence of MS in a dog with spontaneous HAC, and its satisfactory long-term therapeutic resolution. The animal presented marked alterations in addition to the classic symptoms of HAC: discrete hyperglycemia, insulin resistance, hyperlipidemia, arterial hypertension and obesity. Complete resolution of MS and stable control of HAC were observed after five months of treatment.

scholarly journals The Impact of Metabolic Syndrome and Its Components on Female Sexual Dysfunction: A Narrative Mini-Review

2018 ◽  
Vol 12 (2) ◽  
pp. 57-63
Author(s):  
Simona Di Francesco ◽  
Marika Caruso ◽  
Iole Robuffo ◽  
Andrea Militello ◽  
Elena Toniato
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Sexual Dysfunction ◽  
Arterial Hypertension ◽  
Sexual Function ◽  
Sexual Desire ◽  
Female Sexual Dysfunction ◽  
Systemic Arterial Hypertension ◽  
The Metabolic Syndrome ◽  
The Impact

Background: The impact of metabolic syndrome on female sexual dysfunction received modest consideration in clinical practice. The aim of the research was to analyze the international literature to determine the relationship between the metabolic syndrome, its components and female sexual disorders. Methods: We identified relevant full-length papers by electronic databases as Index Medicus/Medline, Scopus, Life Science Journals, from 2005 to the present. Studies were searched using the following as search query: metabolic syndrome, female sexual dysfunction, obesity, systemic arterial hypertension, diabetes mellitus, dyslipidemia. Results: Women with metabolic syndrome showed higher prevalence of sexual inactivity and low sexual desire, orgasm and satisfaction respect to women without metabolic syndrome. Particularly metabolic components as diabetes mellitus, dy-slipidemia, systemic arterial hypertension were strongly associated with lower sexual desire, activity and Female Sexual Function Index total score. In contrast, other studies showed no relationship. Conclusion: Our study showed that in the clinical evaluation of women with metabolic syndrome routine inquiring about female sexual dysfunction should be recommended to ameliorate sexual function and quality of life. However more prospective and longitudinal studies on the sexual effects of metabolic syndrome should also be suggested to know the factors related to women's sexuality better.

scholarly journals Luteolin-Enriched Artichoke Leaf Extract Alleviates the Metabolic Syndrome in Mice with High-Fat Diet-Induced Obesity

Nutrients ◽  
2018 ◽  
Vol 10 (8) ◽  
pp. 979 ◽  
Author(s):  
Eun-Young Kwon ◽  
So Kim ◽  
Myung-Sook Choi
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Hepatic Steatosis ◽  
High Fat Diet ◽  
Acid Oxidation ◽  
High Fat ◽  
Alcoholic Fatty Liver ◽  
Diet Induced Obesity ◽  
The Metabolic Syndrome

This current study aimed to elucidate the effects and possible underlying mechanisms of long-term supplementation with dietary luteolin (LU)-enriched artichoke leaf (AR) in high-fat diet (HFD)-induced obesity and its complications (e.g., dyslipidemia, insulin resistance, and non-alcoholic fatty liver disease) in C57BL/6N mice. The mice were fed a normal diet, an HFD, or an HFD plus AR or LU for 16 weeks. In the HFD-fed mice, AR decreased the adiposity and dyslipidemia by decreasing lipogenesis while increasing fatty acid oxidation, which contributed to better hepatic steatosis. LU also prevented adiposity and hepatic steatosis by suppressing lipogenesis while increasing biliary sterol excretion. Moreover, AR and LU prevented insulin sensitivity by decreasing the level of plasma gastric inhibitory polypeptide and activity of hepatic glucogenic enzymes, which may be linked to the lowering of inflammation as evidenced by the reduced plasma interleukin (IL)-6, IL-1β, and plasminogen activator inhibitor-1 levels. Although the anti-metabolic syndrome effects of AR and LU were similar, the anti-adiposity and anti-dyslipidemic effects of AR were more pronounced. These results in mice with diet-induced obesity suggest that long-term supplementation with AR can prevent adiposity and related metabolic disorders such as dyslipidemia, hepatic steatosis, insulin resistance, and inflammation.

scholarly journals ASSOCIATIONS OF IRS-1 POLYMORPHISM WITH VARIOUS COMPONENTS OF THE METABOLIC SYNDROME IN HYPERTENSIVE PATIENTS

2019 ◽  
Vol 72 (8) ◽  
pp. 1494-1498
Author(s):  
Maryna Kochuieva ◽  
Valentyna Psarova ◽  
Larysa Ruban ◽  
Nataliia Kyrychenko ◽  
Olena Alypova ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Waist Circumference ◽  
Glucose Tolerance ◽  
Arterial Hypertension ◽  
Abdominal Obesity ◽  
Healthy Individuals ◽  
Hypertensive Patients ◽  
The Metabolic Syndrome

Introduction: The metabolic syndrome is one of the most discussed cross-disciplinary problems of modern medicine. Now there are various definitions and criteria of diagnostics of metabolic syndrome. The abdominal obesity is considered the main component of the metabolic syndrome, as a reflection of visceral obesity which degree is offered to be estimated on an indirect indicator – a waist circumference. Alongside with abdominal obesity, a number of classifications distinguish insulin resistance (IR) as a diagnostic criterion of metabolic syndrome. It is proved that IR is one of the pathophysiological mechanisms influencing the development and the course of arterial hypertension (AH), type 2 DM and obesity. There are two components in the development of IR: genetic (hereditary) and acquired. In spite of the fact that IR has the accurate genetic predisposition, exact genetic disorders of its appearance have not been identified yet, thus demonstrating its polygenic nature. The aim: To establish possible associations of the insulin receptor substrate-1 (IRS-1) gene polymorphism with the severity of the metabolic syndrome components in patients with arterial hypertension (AH). Materials and methods: 187 patients with AH aged 45-55 years and 30 healthy individuals. Methods: anthropometry, reactive hyperemia, color Doppler mapping, biochemical blood analysis, HOMA-insulin resistance (IR), glucose tolerance test, enzyme immunoassay, molecular genetic method. Results: Among hypertensive patients, 103 had abdominal obesity, 43 - type 2 diabetes, 131 - increased blood triglycerides, 19 - decreased high density lipoproteins, 59 -prediabetes (33 - fasting hyperglycemia and 26 - impaired glucose tolerance), 126 had IR. At the same time, hypertensive patients had the following distribution of IRS-1 genotypes: Gly/Gly - 47.9%, Gly/Arg - 42.2% and Arg/Arg - 10.7%, whereas in healthy individuals the distribution of genotypes was significantly different: Gly/Gly - 86.8% (p<0.01), Gly/ Arg - 9.9% (p<0.01) and Arg/Arg - 3.3% (p<0.05). Hypertensive patients with Arg/Arg and Gly/Arg genotypes had significantly higher HOMA-IR (p<0.01), glucose, insulin and triglycerides levels (p<0.05), than in Gly/Gly genotype. At the same time, body mass index, waist circumference, blood pressure, adiponectin, HDL, interleukin-6, C-reactive protein, degree of endothelium-dependent vasodilation, as well as the frequency of occurrence of impaired glucose tolerance did not significantly differ in IRS-1 genotypes. Conclusions: in hypertensive patients, the genetic polymorphism of IRS-1 gene is associated with such components of the metabolic syndrome as hypertriglyceridemia and fasting hyperglycemia; it is not associated with proinflammatory state, endothelial dysfunction, dysglycemia, an increase in waist circumference and decrease in HDL.

scholarly journals Impact of subclinical inflammatory markers on the development of cardiovascular pathology in patients with the metabolic syndrome

2021 ◽  
Vol 24 (2) ◽  
pp. 4-11
Author(s):  
Oksana N. Belousova ◽  
Marina V. Chupakha
Keyword(s):  
Oxidative Stress ◽  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Arterial Hypertension ◽  
Endocrine System ◽  
Modern Medicine ◽  
Induce Insulin Resistance ◽  
The Metabolic Syndrome ◽  
Factor Α

Metabolic syndrome currently remains one of the most pressing problems in medicine, since it makes its decisive contribution to the development of cardiovascular diseases and cerebral complications. Another important problem of modern medicine is arterial hypertension, which is one of the constituent criteria of metabolic syndrome, whose mechanism of development is due to a disruption in the work of the renin-angiotensin-aldosterone system, the sympathoadrenal system, an increased content of pro-inflammatory cytokines, as well as an imbalance in the adipokine system. Adipose tissue now acts not just as a structure that provides our body with energy only, but now it acts as an organ of the endocrine system, producing a large number of metabolically active substances. Patients with metabolic syndrome have been found to have elevated levels of proinflammatory cytokines were increased: monocytic chemotactic protein-1 (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). These cytokines are thought to be synthesised by adipose tissue macrophages and are involved in the pathogenesis of the metabolic syndrome. Oxidative stress can induce insulin resistance in adipocytes. The pathogenesis of oxidative stress in adipocytes in MS is still a mystery. This knowledge would be very useful in developing new approaches to MS therapy. Given the significant effect of chemokines in MS on the development of systemic inflammation, insulin resistance, and arterial hypertension, scientists have an important task not only to describe the actions of individual chemokines in hypertension, but also to characterize how the effect on one chemokine modulates the expression and/or function of other chemokines and their related receptors.

ARTERIAL HYPERTENSION AND COMORBIDITY (REVIEW)

2020 ◽  
Vol 2 (1) ◽  
pp. 9-13
Author(s):  
Irina Agababyan ◽  
◽  
Shukhrat Ziyadullaev ◽  
Jamshid Ismailov
Keyword(s):  
Quality Of Life ◽  
Metabolic Syndrome ◽  
Arterial Hypertension ◽  
The Metabolic Syndrome

Today, hypertension is considered by many authors within the framework of the manifestation of the metabolic syndrome. It has been established that in persons with hypertension in 60% of cases, various variants of MS are found. In addition, hypertension is a factor that reduces the quality of life of patients, especially those with comorbid pathology

Role of genetic factors in the development of hypertension in young patients with metabolic syndrome

2020 ◽  
pp. 23-32
Author(s):  
Elena Korneeva ◽  
Mikhail Voevoda ◽  
Sergey Semaev ◽  
Vladimir Maksimov
Keyword(s):  
Metabolic Syndrome ◽  
High Risk ◽  
Arterial Hypertension ◽  
Genetic Factors ◽  
Young Patients ◽  
Integrin Αiibβ3 ◽  
Ace Gene ◽  
The Metabolic Syndrome

Results of the study related to polymorphism of ACE gene (rs1799752)‎, integrin αIIbβ3, and CSK gene (rs1378942) influencing development of arterial hypertension in young patients with metabolic syndrome are presented. Hypertension as a component of the metabolic syndrome was detected in 15.0% of young patients. Prevalence of mutant alleles of the studied genes among the examined patients was quite high, so homozygous DD genotype was found in 21.6%, and mutant D allele of the ACE gene in 47.4%. A high risk of hypertension in patients with MS was detected in carriers of the T allele of the CSK (rs1378942) gene – 54.8%, which was most often observed in a combination of polymorphic ACE and CSK gene loci (p = 0.0053).

Metabolic Syndrome During Menopause

2019 ◽  
Vol 17 (6) ◽  
pp. 595-603 ◽  
Author(s):  
Sezcan Mumusoglu ◽  
Bulent Okan Yildiz
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Central Obesity ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Natural Menopause ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Aging Women

The metabolic syndrome (MetS) comprises individual components including central obesity, insulin resistance, dyslipidaemia and hypertension and it is associated with an increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). The menopause per se increases the incidence of MetS in aging women. The effect(s) of menopause on individual components of MetS include: i) increasing central obesity with changes in the fat tissue distribution, ii) potential increase in insulin resistance, iii) changes in serum lipid concentrations, which seem to be associated with increasing weight rather than menopause itself, and, iv) an association between menopause and hypertension, although available data are inconclusive. With regard to the consequences of MetS during menopause, there is no consistent data supporting a causal relationship between menopause and CVD. However, concomitant MetS during menopause appears to increase the risk of CVD. Furthermore, despite the data supporting the association between early menopause and increased risk of T2DM, the association between natural menopause itself and risk of T2DM is not evident. However, the presence and the severity of MetS appears to be associated with an increased risk of T2DM. Although the mechanism is not clear, surgical menopause is strongly linked with a higher incidence of MetS. Interestingly, women with polycystic ovary syndrome (PCOS) have an increased risk of MetS during their reproductive years; however, with menopausal transition, the risk of MetS becomes similar to that of non-PCOS women.

C-Peptide and its Correlation to Parameters of Insulin Resistance in the Metabolic Syndrome

2011 ◽  
Vol 10 (8) ◽  
pp. 921-927 ◽  
Author(s):  
Shaheena Banu ◽  
Nasimudeen R. Jabir ◽  
C. N. Manjunath ◽  
Shazi Shakil ◽  
Mohammad A. Kamal
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
C Peptide ◽  
The Metabolic Syndrome
Sign in / Sign up

Export Citation Format

Share Document